Phosphodiesterase 5 expression in photoreceptors rescues retinal degeneration induced by deregulation of membrane guanylyl cyclase.

J Biol Chem

Gavin Herbert Eye Institute, Department of Ophthalmology and Center for Translational Vision Research, University of California, Irvine, California, United States; Department of Physiology and Biophysics, University of California, Irvine, California, United States.

Published: February 2025

Mutations in retinal membrane guanylyl cyclase 1 (RetGC1) and its calcium-sensor protein (guanylyl cyclase activating protein 1, GCAP1) cause congenital dominant retinopathies by elevation of cGMP synthesis in photoreceptors in the dark. We explored counteracting the elevated cGMP synthesis causing photoreceptor degeneration using ectopic expression of a nonphotoreceptor cGMP phosphodiesterase (PDE) isozyme PDE5. PDE5 primary structure was modified to direct the delivery of the recombinant PDE5 (PDE5r) to rod outer segments, by placing a C-terminal fragment derived from a cone-specific alpha-subunit of PDE6C at the C terminus of the PDE5, which allowed PDE5r expressed under control of mouse rod opsin promoter to accumulate in rod outer segments. Expression of PDE5r did not affect calcium-sensitivity of RetGC regulation in PDE5r transgenic retinas, but increased cGMP hydrolysis in the dark, which partially desensitized PDR5r rods in the dark via an "equivalent light" effect, analogous to exposure to a constant dim light of ∼20 to 40 photons μm sec. The calcium-sensitivity of RetGC regulation remained drastically shifted outside the normal physiological range in hybrid R838SPDE5r rods expressing both PDE5r and R838S RetGC1, the mutant causing GUCY2D dominant retinopathy, but the hybrid rods demonstrated a dramatic rescue from degeneration caused by the R838S RetGC1. In a similar fashion, PDE5r expression rescued degeneration of rods harboring Y99C GCAP1, one of the GCAP1 mutants most frequently causing GUCA1A dominant retinopathy. Our results open a possibility that ectopic expression of PDE5 can be used as an approach to rescue presently incurable dominant GUCY2D and GUCA1A retinopathies at the expense of a moderate reduction in rod light-sensitivity.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbc.2025.108265DOI Listing

Publication Analysis

Top Keywords

guanylyl cyclase
12
membrane guanylyl
8
cgmp synthesis
8
ectopic expression
8
rod outer
8
outer segments
8
calcium-sensitivity retgc
8
retgc regulation
8
r838s retgc1
8
dominant retinopathy
8

Similar Publications

Natriuretic peptides (NPs) bind to glomerular podocytes and attenuate glomerular injury. The beneficial effects of NPs are negatively regulated by the NP clearance receptor (NPRC), which is highly expressed in podocytes. To determine if inhibiting NPRC is podocyte protective, we examined the effects of deleting NPRC in both cultured podocytes and in vivo.

View Article and Find Full Text PDF

The effect of the nitric oxide donor S-nitrosoglutathione on the level and activity of organic anion transporting polypeptide 1B1 (OATP1B1), as well as the expression of the SLCO1B1 gene encoding the transporter protein, was investigated in HepG2 cells. The study has shown that treatment of cells with S-nitrosoglutathione for 3 h did not influence the content and activity of OATP1B1. Incubation with S-nitrosoglutathione (10-500 μM) for 24 h increased SLCO1B1 expression, the content of OATP1B1, and activity of the transporter protein.

View Article and Find Full Text PDF

Objective: Arterial stiffness, or loss of elastic compliance in large arteries, is an independent precursor of cardiovascular disease (CVD) and dementia . Akin to anti-hypertensive and lipid-lowering drugs, arterial de-stiffening therapies could be beneficial at decreasing CVD risk. We previously discovered that enhanced cytoskeletal actin polymerization in vascular smooth muscle cells (VSMCs) contributes to increased arterial stiffness .

View Article and Find Full Text PDF

Background: Type-II diabetes (DMII) and metabolic syndrome increase ventricular arrhythmia and sudden cardiac death risk.

Objectives: To identify signaling mechanisms through which DMII and metabolic syndrome promote ventricular tachycardia (VT).

Methods: We performed ventricular programmed stimulation on leptin receptor mutant (Db/Db) mice with DMII, high fat high sucrose (HFHS)-fed mice with metabolic syndrome, and cGMP-dependent Protein Kinase 1α (PKG1α) leucine zipper mutant (LZM) mice, which do not have DMII or metabolic syndrome but have disrupted PKG1α signaling.

View Article and Find Full Text PDF

Methylene Blue for the Treatment of Refractory Hypotension in Polysubstance Overdose.

Cureus

January 2025

Emergency Medicine, Summa Health, Akron, USA.

Methylene blue is commonly used for methemoglobinemia and vasoplegia following coronary artery bypass procedures but has recently been investigated as a treatment for refractory hypotension. One such cause of refractory hypotension is overdose of calcium channel blocker medications. This case presents a patient with polysubstance overdose and refractory hypotension that improved with methylene blue infusion.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!